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Systemic environmentChanges of factors circulating in the systemic environment during human aging have been investigated for a
long time. Only recently however, miRNAs have been found to be secreted into the systemic and tissue envi-
ronments where they are protected from RNAses by either carrier proteins or by being packaged into
microvesicles. These miRNAs are then taken up by recipient cells, changing the cellular behavior by the clas-
sical miRNA induced silencing of target mRNAs. The origin of circulating miRNAs, however, is in most in-
stances unclear, but senescent cells emerge as a possible source of such secreted miRNAs. Since differences
in the circulating miRNAs have been found in a variety of age-associated diseases, and accumulation of senes-
cent cells in the elderly emerges as a possible detrimental factor in aging, it is well conceivable that these
miRNAs might contribute to the functional decline observed during aging of organisms.
Therefore, we here give an overview on current knowledge on microvesicular secretion of miRNAs, changes
of the systemic and tissue environments during aging of cells and organisms. Finally, we summarize current
knowledge on miRNAs that are found to be speciﬁc for age-associated diseases.
© 2013 Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
Although much progress has been achieved in aging research over
the past decades, the individual heterogeneity of the aging process in
humans still remains puzzling and one of the major challenges for our
societies. It is therefore mandatory to improve our understanding of
the normal aging process, as aging is the substrate on which age-
associated diseases will grow. Such a functional understanding on a
molecular level might help to design strategies for prevention and
therapy of the age-related losses in cell, tissue and organism
functionalities.
Here we will summarize current knowledge on the secretion of
miRNAs and their potential impact on cellular and organismal aging
processes.required for transport; ILV,
ger RNA; MVB, multivesicular
rane; Rab, Ras-related in brain;
A; SASP, senescence-associated
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ari).
ND license.2. Cellular senescence, organismal aging, and the
systemic environment
2.1. Cellular senescence
Senescent cells have been widely studied as a model system of
aging ever since the replicative limit of normal human somatic cells
in culture had been described by Hayﬂick more than four decades
ago (Hayﬂick, 1965). Senescent cells are characterized by a combina-
tion of changes in cell behavior, structure and functions including an
irreversible growth arrest, resistance to apoptosis and alteration in
gene expression (Campisi and d'Adda di Fagagna, 2007). Moreover,
a senescent phenotype is also induced by various physico-chemical
stressors that induce DNA damage and chromatin disruption as well
as by oncogenic signals (Cabrera et al., 1992; Maruyama et al.,
2009). Since senescent cells never re-enter the cell cycle, cellular
senescence is suggested to prevent malignant transformation of
potentially mutated cells and thus contributes to tumor suppression.
In contrast, senescent cells persist within tissues and are not eliminat-
ed by apoptosis, and their altered functional proﬁle alters tissue
microenvironments in ways that can promote both cancer and
aging phenotypes (Krtolica and Campisi, 2002; Rodier et al., 2007).
Recently it was shown that premalignant mammary epithelial cells
exposed to senescent human ﬁbroblasts in mice irreversibly lose
differentiated properties, become invasive and undergo full malig-
nant transformation (Parrinello et al., 2005).
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By now, the presence and age-related accumulation of senescent
cells in vivo have become well accepted (Campisi and d'Adda di
Fagagna, 2007; Campisi and Sedivy, 2009) and it is well established
that senescent cells in vivo contribute to age-associated diseases
like atherosclerosis (Erusalimsky, 2009; Erusalimsky and Skene,
2009; Minamino and Komuro, 2007). Moreover it was shown that
cellular senescence limits the extent of ﬁbrosis following liver
damage and underscores the interplay between senescent cells and
the tissue microenvironment (Krizhanovsky et al., 2008).
In spite of these variously good and bad effects of cellular senes-
cence, recent studies support the idea that accumulation of senescent
cells with the aging of organisms accelerates age-associated diseases
and loss of tissue function (Baker et al., 2011). In addition, the
reactivation of telomerase in mice delays the onset of loss of tissue
functionality (Jaskelioff et al., 2011), and even increases mouse life
span (Bernardes de Jesus et al., 2012).
2.3. Senescent cells and their microenvironment
Besides the altered functionality of the cells themselves,
detrimental effects of senescent cells might be due to an altered
secretion phenotype. Indeed, senescent cells develop a senescence-
associated secretory phenotype (SASP), where cytokines, extracellu-
lar matrix proteins and proteases, as well as other factors that alter
the behavior of neighboring cells have been found. The senescent
secretome of ﬁbroblasts has been well established by the identiﬁca-
tion of various secreted factors that contribute to senescence like
insulin-like growth factor binding protein 7 (IGFBP7) (Wajapeyee et
al., 2008), interleukin-8 (IL-8) receptor binding chemokines (Acosta
et al., 2008a, 2008b), IL-6 (Kuilman and Peeper, 2009), but also key
components of the Wnt pathway, insulin-like growth factor 1
(IGF1), transforming growth factor-β (TGFβ), and plasmin (Kuilman
and Peeper, 2009). The SASP includes inﬂammatory cytokines that
are thought to drive aging and age-related disease (Finch and
Crimmins, 2004). Indeed, some SASP factors, when chronically pres-
ent, can disrupt tissue structure and differentiation (Parrinello et al.,
2005), and others can promote malignant phenotypes in nearby pre-
malignant cells (Bavik et al., 2006; Coppé et al., 2008; Krtolica et al.,
2001; Liu and Hornsby, 2007). On the other hand, some SASP factors
may be beneﬁcial. For example, some reinforce the senescence
growth arrest in an autocrine manner (Acosta et al., 2008b; Kuilman
and Peeper, 2009; Kuilman et al., 2008). Others may allow damaged
cells to communicate their compromised state (Rodier et al., 2009)
in order to stimulate tissue repair or limit pathology (Krizhanovsky
et al., 2008).
2.4. Senescent cells, the systemic environment and miRNAs
Accumulation of damage in cells and tissues has been accepted as
one of the major driving forces of aging and age related diseases
(Kirkwood, 2005). Several systemic factors have been found to change
with age so far, among them chemokines like chemokine (C–C motif)
ligand 11 (CCL11), whose levels correlate with neurogenesis (Villeda
et al., 2011), and hormones like the growth hormone (Corpas et al.,
1993) as well as the sulfated form of dehydroepiandrosterone
(Baulieu, 1996).
In most tissues, there is an age-related decline in stem cell func-
tionality but not a depletion of stem cells. Their ability to self-renew
and differentiate is essential for homeostasis and regeneration of
tissue and organs. The functionality of these cells declines with age
(Rando, 2006). One factor that contributes to this functional decline
is the systemic environment of old organisms (Conboy et al., 2005).
This decline in functionality might be either due to factors that active-
ly inhibit successful tissue regeneration or due to the absence ofpromoting factors in the elderly. In contrast, factors present in the
systemic environment of young animals promote successful tissue re-
generation (Matsumoto et al., 2009).
Such factors are still largely unknown, but some are slowly emerg-
ing. Among these are proteins, Wnt, TGF-β (Carlson et al., 2009) and
IGF-1 signaling molecules (Mayack et al., 2010) that are suspected to
be factors contributing to the functional decline. However, the source
of such factors is currently unknown. It can be imagined that any
other types of endocrine and inﬂammatory signaling molecules by
their presence or absence might contribute to such an impairment
of tissue functionality.
Recently, such “endocrine” functions have been attributed to
miRNAs, as miRNAs are not only found intracellularly, but are also
detectable outside of the cells, including various body ﬂuids (e.g.,
serum, plasma, saliva, urine and milk) (Chen et al., 2012), where
they circulate unimpeded by RNAses due to association with protec-
tive proteins or by being packaged into microvesicles (Viaud et al.,
2008). But how are miRNAs generated, and how do they end up in
microvesicles?
3. Microvesicular miRNAs
3.1. MicroRNA biogenesis and turnover
MiRNAs comprise a large family of ~21-nucleotide-long RNAs that
have emerged as key post-transcriptional regulators of gene expres-
sion and have revolutionized our comprehension of the post-
transcriptional regulation of gene expression. miRNAs are processed
from primary transcripts (pri-miRNAs), which are either transcribed
by RNA polymerase II from independent genes or represent introns
of protein-coding genes. Pri-miRs are then processed to precursor
miRNAs (pre-miRs) by the RNA endonucleases Drosha and Pasha
and are exported to the cytoplasm where dicer cuts the pre-miRs
into the mature miRNA duplexes. The mode of action in silencing
depends on the recognition of target mRNAs by single stranded
miRNAs that get incorporated into the RNA induced silencing com-
plex (RISC). Binding may depend on the “seed” region consisting of
nucleotides 2–8 of the miRNA only. One miRNA is able to regulate
up to hundred mRNA targets and therefore seems to orchestrate a
large variety of cellular processes similar to transcription factors
(Lim et al., 2005; Stefani and Slack, 2008), but also in concert with
transcription factors forming feed forward loops (Shalgi et al.,
2007).
In contrast to miRNA biogenesis, turnover of miRNAs has received
only limited attention to date. It is generally thought that miRNAs
represent highly stable molecules and, experimentally using RNA po-
lymerase II inhibitors or depletion of miRNA processing enzymes,
have indicated that the half-lives of miRNAs in cell lines or in organs
such as liver or heart correspond to many hours or even days
(Gatﬁeld et al., 2009; Großhans and Chatterjee, 2010; Krol et al.,
2010; van Rooij et al., 2007).
miRNA stability is inﬂuenced by the 3′ end sequence motif or
modiﬁcation that mark miRNAs for degradation or protect them
against exonucleolytic activity, depending on the speciﬁc miRNAs
and the tissues. In liver cells, a single adenine residue added to the
3′ end of miR-122 prevents trimming and protects the miRNA against
exonucleolytic degradation (Katoh et al., 2009).
3.2. Microvesicles
It was long believed that the way of communication between cells
and tissues depends to a large extent on protein-based signaling sys-
tems exempliﬁed by soluble secreted factors like cytokines,
chemokines, neurotransmitter, enzymes and hormones. In principle
there were two classes of signaling systems described. One system
depends on direct cell–cell contact (also known as juxtacrine
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bridges or synaptic connections. On the other hand a second contact
independent system has been described. In the latter case soluble
factors are either secreted into the intercellular space where they
are able to effect nearby cells (also known as paracrine signaling) or
into the circulation where they can cover long distances and affect
faraway recipient cells (also known as endocrine signaling).
With the recent discovery of microvesicles a new mechanism of
cell communication participating in the contact independent system
was proposed. Microvesicles are vesicles which bud from a cellular
membrane and contain, depending on their origin, proteins, mRNAs,
miRNAs and/or DNA (Mathivanan et al., 2010a). In contrast to the
abovementioned and well understood protein-based signaling sys-
tems, microvesicles have the advantage that they deliver not only
one but multiple (potentially synergistic) messages, whereby they
might be able to inﬂuence and change the cellular behavior at several
stages of protein expression allowing rapid control over targeted
cells.
Microvesicles were found to be produced by various cells e.g. by
dentritic cells, mast cells, B-cells, T-cells, platelets, but also in neurons,
oligodentrocytes, epithelial cells, endothelial cells, embryonic ﬁbroplast
cells, microglia, neuroglial cells and several tumor cell lines to name but
a few (Hu et al., 2012; Mathivanan et al., 2010a). Furthermore they
were also found in several body ﬂuids such as serum, plasma, urine, oc-
ular ﬂuids, amniotic ﬂuid, ascites, broncheoalveolar lavage, cerebrospi-
nal ﬂuid, seminal plasma, breast milk, tears and saliva (Cocucci et al.,
2009; Hu et al., 2012; Mathivanan et al., 2010a; Pant et al., 2012; Zhu
and Fan, 2011).
3.3. The Babylonian language problem
To date, three different types of microvesicles seem to crystallize
out of a plethora of names (Table 1): ectosomes, exosomes and apo-
ptotic blebs. In principle they are distinguished by their size, shape,
density, origin as well as protein membrane composition (Mathivanan
et al., 2010a; Thery et al., 2009).
However, no commonly accepted nomenclature for microvesicles
has yet been established, resulting in a confusing and confounding
terminology. For example several names such as microparticles,
microvesicles, nanoparticles, shedding microvesicles, ectosomes,
exosomes, exosome-like vesicles, dexosomes, texosomes, oncosomes,
apoptotic blebs, apoptotic bodies, to name a few were used for a
mixed population of microvesicles. Only recently, we have begun to
understand that in body ﬂuids different species of vesicles exist and
that we need to isolate them based on differences in composition,Table 1
Comparison of microvesicle types.
Exosomes Ectosomes Apoptotic bodies
Size [nm] 30–100 nm 100–1000 nm 50–5000 nm
Floating
density [g/ml]
1.10–1.21 N.K. 1.16–1.28
Sedimentation
[g]
100,000–110,000 10,000–100,000 1500–100,000
Cargo mRNA, miRNA, proteins mRNA, miRNA,
proteins
mRNA, miRNA,
rRNA, DNA,
proteins
Origin Late endosomes Plama membrane Apoptotic cells
Speciﬁc
marker
Tetraspanins(CD81,
CD63) ESCRT member
(Alix, TSG 101)
Integrins, selectins,
metalloproteinases
Histones, DNA
Morphology Cup shaped Irregularly Irregularly
Uptake of
cargo
Speciﬁc Speciﬁc N.K.
Mode of
release
Fusion of MVB with PM PM blebbing by
actomyosin
contraction
PM blebbing by
actomyosin
contractionsize or shape as done in a couple of recent reports (Mathivanan et
al., 2010b). Therefore, a close look on the performed isolation method
of vesicles is highly recommended when reading literature and a
commonly agreed terminology would be highly welcome.
4. Biogenesis of microvesicles
4.1. Exosomes
Exosomes are small cup shaped membrane vesicles of 30–100 nm
in diameter which originate from the endosomal compartment
(Simpson et al., 2008, 2009). The name goes back to 1983, when
Pan and Johnstone described microvesicles responsible for externaliz-
ing receptors during erythrocyte maturation, which are formed by in-
ward budding of vesicles into the late endosomal compartment (Pan
and Johnstone, 1983). Such inward budding of the late endosomal
limiting membrane, is by now known to encapsulate cytosolic
‘cargo’ into intraluminal vesicles (ILV) whereby large multivesicular
bodies (MVB) are formed (van Niel et al., 2006). MVBs enriched in
ILV can either fuse with lysosomes, if their content is intended for
degradation or with the plasma membrane whereby ILVs are released
into the extracellular space as “exosomes” (Simpson et al., 2009).
Although it is still unknown how the formation of MVBs works on
a molecular basis, mechanisms have been proposed.
The ﬁrst requires the ESCRT (endosomal sorting complex required
for transport) machinery to comprise mainly mono ubiquitinated
cargo for lysosomal degradation (Babst, 2005). The formation of the
second type of MVBs is based on an alternative mechanism involving
lipid rafts enriched in sphingolipid ceramide (Trajkovic et al., 2008).
The third mechanism was proposed by Rana et al. assuming that
proteins are incorporated by special membrane domains resistant to
detergents because of their lipid composition and enriched in
tetraspanin (Rana and Zöller, 2011).
Whichever mechanism or combination of mechanisms will be op-
erative, several necessary components for exosome formation have
by now been identiﬁed, e.g., Ras-related in brain 27a (Rab27a)
which inﬂuences the size of MVBs (Ostrowski et al., 2010), Rab27b
which is controlling the direction of MVBs (Ostrowski et al., 2010),
Rab35 which contributes to the docking of exosomes to the plasma
membrane (Hsu et al., 2010), hepatocyte growth factor receptor sub-
strate (Hrs) which is necessary for ILV formation (Razi and Futter,
2006), soluble N-ethylmaleimide-sensitive-factor attachment recep-
tors (SNAREs) having a role in the fusion process of MVBs and the cel-
lular plasma membrane (Bobrie et al., 2011) and myosins (Pant et al.,
2012).
4.2. Ectosomes
Stein and Luzio deﬁned ectosomes as right-side-out-orientated
vesicles containing cytosolic components which are released from
the surface of polymorphonuclear leucocytes attacked by a comple-
ment (Stein and Luzio, 1991). Today the term “ectosomes” is used
in a more general way and deﬁned as microvesicles which directly
bud from the cellular plasma membrane. Ectosomes are of irregular
shape and vary in size between 100 and 1000 μm (Mathivanan et
al., 2010a). In contrast to the plasma membrane that they originate
from, they expose phospholipid phospatidylserine (PS) on their
surface (Zwaal and Schroit, 1997). Furthermore they contain
metalloproteinases, which were shown to inﬂuence the extracellular
space thereby promoting tumor metastasis and invasion, selectins
and integrins (Coppé et al., 2008; Mathivanan et al., 2010a).
Ectosomes are continuously produced by many if not all cells in
vitro but the stimulating agents, which are able to enhance their
production, vary between the different cell types (Sadallah et al.,
2011). In addition they contain proteins, mRNAs and miRNAs. The
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agent (Cocucci and Meldolesi, 2011).
For the shedding of ectosomes a local disassembly of the cytoskel-
eton as well as the vesicle abscission process is necessary (Cocucci
and Meldolesi, 2011). Therefore increasing cytosolic Ca2+ concentra-
tions, activated p38 MAPK Curtis et al. (2009), acid sphingomyelinase
(Bianco et al., 2009) and the Rho–ROCK axis (Pinner and Sahai, 2008)
as well as the regulative enzymes calpain, a calcium-dependent cyto-
solic protease (Miyoshi et al., 1996), ﬂippase, ﬂoppase, scramblase
and gelosin were shown to be involved (Enjeti et al., 2008).
4.3. Apoptotic blebs
Apoptotic blebs are released by cells during the late stage of apo-
ptosis through pinching off from the cellular plasma membrane
(Beyer and Pisetsky, 2010). The abscission of apoptotic blebs is
performed through the intracellular increase of the hydrostatic pres-
sure followed by the cellular contraction with the aid of actomyosin
(Charras et al., 2005, 2008). They are greater than 50 nm in diameter
and of irregular shape (Mathivanan et al., 2010a). They contain pro-
teins, mRNAs, miRNAs as well as DNA and expose phosphatidylserine
(Théry et al., 2001).
5. Packaging of miRNAs into vesicles and releasing to the
cellular environment
In 2007 Valadi and coworkers were the ﬁrst to show that miRNAs,
besides mRNAs and proteins, are packaged into microvesicles (Valadi
et al., 2007). Surprisingly, the miRNA content of microvesicles does
not necessarily correspond to the cytosolic repertoire of miRNAs,
as the miRNA proﬁle of hepatocellular cancer cells and their
microvesicles does differ (Kogure et al., 2011). Only 134 of 424
cellular detectable miRNAs were also found in the exosomes of
hepatocellular cancer cells. Of these 134 vesicular miRNAs, 25 were
higher and 30miRNAs were less expressed compared to the intracellu-
larmiRNA expression levels. Interestingly, 11miRNAswere solely iden-
tiﬁed inmicrovesicles, strongly suggesting that a speciﬁc and controlled
packaging mechanism needs to exist (Kogure et al., 2011).
So far, only the ﬁrst indications on this mechanism are known
from studies using human monocytes, where mRNAs, miRNAs and
components of the RNA-induced silencing complexes (RISCs) are
concentrated in GW-bodies, which are distinct foci within the cyto-
plasm where many necessary proteins for miRNA gene silencing ac-
cumulate. These GW-bodies accumulate at the membrane of late
endosomes and MVBs which might facilitate the loading of RNA into
exosomes thereby contributing to intercellular transport or post-
transcriptional control of intracellular miRNA levels (Gibbings and
Voinnet, 2010). Although all components of RISC were found to be
localized at the membranes of late endosomes and MVBs, only trinu-
cleotide repeat containing 6 (TNRC6), pre-miRNAs, fragments of
pre-miRNA stem loops and miRNAs were found to be enriched within
exosomes (Chen et al., 2010; Gibbings et al., 2009). It is known that
TNRC6 directly binds to Argonaute (Ago) thereby initiating the
mRNA decay (Chen et al., 2009). A mutant of TNRC6 lacking, in its
C-terminus, caused a reduced miRNA activity and the accumulation
of miRISC (AGO, miRNA, mRNA and TNRC6) indicating that its
C-terminus might be necessary for the dissociation of miRISC (Zekri
et al., 2009). Poly(A) binding protein (PABP) which potentially
binds at the C-terminus of TNRC6 was shown to bind directly to
tumor susceptibility gene 101 (TSG101) thereby providing the link
between the RISC complex and exosomes (Schlundt et al., 2009).
Interestingly similar inhibiting effects on miRISC dissociation and
reduced levels of exosomal TNRC6 were observed when ESCRT was
knocked out, suggesting that ESCRT is necessary for sorting TNRC6
into exosomes (Gibbings et al., 2009). In addition ESCRT II might
have a role in sorting miRNA into exosomes since it is able to bindRNA directly (Irion and St Johnston, 2007). Summarizing functional
links between miRNAs and the ESCRT machinery, where RISC as
well as the ESCRT complex might work together in a common path-
way to load miRNAs into exosomes were found.
In contrast, neutral sphingomyelinase 2 (nSMase2), which is reg-
ulating the biosynthesis of ceramide, but not the ESCRT machinery
is necessary for the production of exosomes and their enclosed
miRNAs in human T cells (Mittelbrunn et al., 2011). This indicates
that the uptake of miRNAs by the aid of the ESCRT machinery may
not be the only miRNA loading mechanism and might depend on
the cell type and condition.
Packaging of miRNAs into ectosomes is currently even less under-
stood. It is assumed that ectosomes shed from plasma membrane
regions enriched in lipid rafts and that proteins, mRNAs and miRNAs
supposed to be packaged into ectosomes, accumulate at these regions
(Cocucci and Meldolesi, 2011). However, there are several indepen-
dent studies indicating that ectosomes mainly contain mRNAs and
show lower levels of miRNAs compared to exosomes. Skog et al.
determined in 2008 by bioanalyzer that ectosomes originating from
glioblastoma cells predominantly contain mRNAs and barely miRNAs
(Skog et al., 2008).
In any case, packaging of miRNAs into vesicles is a key step for
protecting the miRNAs against the ubiquitous RNAses in the extracel-
lular space, clearly necessary for the stability of extracellular miRNAs,
which are reportedly more resistant against extreme temperatures,
extreme pHs, prolonged storage and freeze–thaw cycles (Chen et al.,
2008; Mitchell et al., 2008).6. Microvesicular miRNAs: uptake mechanisms by target cell
After packagingmiRNAs into microvesicles, they can be transported
through the interstitium or even the peripheral blood (Hunter et al.,
2008). Interestingly microvesicular miRNAs were also found in serum
(Skog et al., 2008), breast milk (Kosaka et al., 2010) and saliva
(Michael et al., 2010). Recently it was shown that engineered
microvesicles expressing a neuron speciﬁc peptide fused to the surface
marker CD107b, are even able to cross the blood–brain barrier and to
deliver siRNA to murine neurons, microglia and oligodendrocytes after
their intravenous injection (Alvarez-Erviti et al., 2011).
The ﬁrst RNAs to be proven as functionally delivered and translat-
ed by microvesicles were mRNAs originating from mouse mast cells.
Their vesicular transport to human mast cells resulted in the expres-
sion of three mouse proteins in human cells (Valadi et al., 2007).
In terms of miRNAs, by now several independent studies demon-
strate, that functional microvesicular miRNAs are taken up by
targeted cells in a sufﬁcient amount to repress the translation of tar-
get genes. For example in 2010 the group of Pegtel observed a
microvesicular transport of miR-150 from THP-1 to HMEC-1 cells
and the consequent silencing of its target c-Myb in the recipient
cells (Zhang et al., 2010).
These results also make clear that our current transfection proce-
dures might work so well since they just mimic the natural transfer
of RNA and DNA species via microvesicles. But how are the
microvesicular miRNAs then taken up by the target cells? There are
two mechanisms that have been observed so far.6.1. Plasma membrane fusion
Exosomes can be transferred between dendritic cells (DC) and are
taken up by membrane fusion. Through the expression of a GFP-
tagged exosomal surface marker protein by the cells of origin, the
recipient plasma membrane exhibited ﬂuorescing GFP patterns after
exosomal uptake. This is taken as a proof that vesicles are taken up
by membrane fusion (Montecalvo et al., 2012).
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By live-cell microscopy Tian et al. observed that microvesicles
from rat PC-12 cells can be efﬁciently taken up by endocytosis and
consequently transferred to the perinuclear region probably mediat-
ed by the cytoskeleton (Tian et al., 2010). Similarly, we recently
observed a reduced uptake of microvesicles originating from endo-
thelial cells by human mesenchymal stem cells (MSCs), when endo-
cytosis of MSCs was blocked by the overexpression of a dominant
negative dynamin construct (K44A) (Schraml et al., unpublished data).
7. Functional consequences of microvesicular miRNA uptake
Several functions of microvesicles were demonstrated in recent
years including effects on cell growth, proliferation, development,
differentiation and cell death as well as on coagulation, the immuno-
logical processes, viral infections, prion infections and cancer progres-
sion (Janowska-Wieczorek et al., 2005; Vlassov et al., 2012; Zhu and
Fan, 2011). By now, several examples exist showing that the transfer
of miRNAs to target cells results in changes of the target cell behavior
strongly indicating that microvesicular miRNAs do indeed make part
of the cell to cell communication system. Such examples come mainly
from studies in the cancer ﬁeld, where microvesicles isolated from
the highly metastatic gastric cancer cell line AZ-P7a secrete increased
levels of the let-7 miRNA family compared to low metastatic AZ-521.
Let-7 miRNAs are known to function in tumor suppression since they
target the oncogenes RAS and HMGA2. It is assumed, that metastatic
AZ-P7a cells release let-7 miRNAs via microvesicles in order to get
rid of this tumor suppressive miRNAs and to maintain their own
tumorigenesis (Ohshima et al., 2010).
Similarly, several examples in the immune system exist. Unidirec-
tional transfer of miRNA within CD63 positive exosomes, derived
from T cells to antigen-presenting cells was shown (Mittelbrunn et
al., 2011). Furthermore miRNAs circulating in human breast milk
might support the development of the infants' immune system
(Kosaka et al., 2010) and miRNA transfer by microvesicles seems
also important in viral infection or defense (Pegtel et al., 2010).
8. Aging, senescence and microvesicular miRNAs
Recently, it has been reported that in both replicative and cell
damage-driven senescence, cells increase overall secretion, termed
SASP, which is characterized by the secretion of a wide variety of
factors, including peptide hormones, as well as the release of
microvesicles (Acosta et al., 2008a, 2008b; Campisi, 2008; Campisi
and d'Adda di Fagagna, 2007). Of note, this secretory activity and
microvesicle formation in senescent cells is also regulated by p53
(Yu et al., 2006).
It is known that miRNAs have some inﬂuence on the aging process
(Gorospe and Abdelmohsen, 2011; Hackl et al., 2010), but little is
known in regard to the systemic environment. So far, several studies
have compared samples from young versus healthy elderly individ-
uals of different species from worm to human tissues in regard to
the intra-cellular miRNA expression proﬁle. Indeed, different expres-
sion levels of several miRNAs have been found with age, e.g., the
miR-17-92 cluster (Hackl et al., 2010) let-7 (Peng et al., 2012) and
miR-34a (Li et al., 2011). Upregulation of speciﬁc miRNAs seems to
induce senescence in cells, among them miR-34a in human cells
(Christoffersen et al., 2010), miR-203 in melanoma cells (Noguchi et
al., 2012) and miR-101, miR-137 and miR-668 in keratinocytes
(Shin et al., 2011).
While not much has been published on miRNA secretion during
the process of aging, it becomes increasingly clear that miRNAs
might be biomarkers of several age-associated diseases. Since several
of these diseases seem to be connected to the increase of senescent
cells, we summarize in the following the current knowledge onmiRNAs that have been found in the serum or plasma of such patients
(Fig. 1).
9. Microvesicular miRNAs in age-associated diseases
The promises of miRNAs as diagnostics and therapeutics are very
high even if we are only at the beginning of developing this RNA
species into biomedical tools. Still, we are convinced that the need
for personalized medicine will boost the search and identiﬁcation of
single miRNAs and/or miRNA signatures characterizing speciﬁc
patients and thus will help in guiding therapies. This seems an urgent
need considering that 90% of the available drugs are efﬁcient only in
40% of the patients.
9.1. Cardiovascular disease
Cardiovascular diseases are the primary cause of death and cause
for many conditions that severely impact on the quality of life at old
age. Endothelial cells seem to counteract this as they secrete
microvesicles, containing miR-143 and miR-145 that are taken up
by VSMC preventing VSMC de-differentiation (Hergenreider et al.,
2012). Injection of vesicles containing both miRNAs into ApoE−/−
mice then indeed resulted in reduced atherosclerotic lesion formation
(Hergenreider et al., 2012). In addition, it was found that deregulation
of both miRNAs contributes to aberrant VSMC plasticity occurring
during vascular diseases (Jakob and Landmesser, 2012).
During atherosclerosis, miR-126 has been found to be secreted via
apoptotic blebs by endothelial cells. This in turn enhances the produc-
tion of the anti-inﬂammatory chemokine CXCL12 as well as its recep-
tor CXCR4 and promotes the recruitment of endothelial progenitor
cells supposedly as a protective mechanism, where the progenitor
cells help to maintain tissue homeostasis (Zernecke et al., 2009).
The protective role of miR-126 was demonstrated also in vivo when
apoptotic blebs enriched in miR-126 originating from human umbili-
cal vein endothelial cells (HUVECs) were injected into high fat diet
ApoE−/− mice, resulting in a reduced lesion size and macrophage
accumulation through CXCR4 expression (Zernecke et al., 2005).
Counterintuitively, downregulation of miR-126 in the plasma of
patients suffering from coronary artery disease has been reported
(Fichtlscherer et al., 2011). It might be speculated, that the targeted
transport of vesicular miRNAs to the sites of atherosclerotic lesions
could cause a reduced detection of freely circulating miRNA levels
(Zhu and Fan, 2011).
Moreover microvesicles also protect against progression of
chronic kidney damage by inhibiting capillary refraction,
glomerulosclerosis, and tubulointerstitial ﬁbrosis by delivering
pro-angiogenic miR-126 and miR-296 (Cantaluppi et al., 2012).
In any case, these studies taken together indicate that endothelially
derived miRNA carryingmicrovesicles might contribute to the progres-
sion of atherosclerosis.
9.2. Neurodegenerative diseases
Alzheimer's disease is the most frequent neurodegenerative
disease in humans. It is characterized by the incident of amyloid
plaques, which are insoluble extracellular depositions containing
amyloid beta peptide (Aβ) (Cai et al., 1993). In Alzheimer's patients,
typical exosomal markers were found to be located at sites of amyloid
plaques (Rajendran et al., 2006), giving a ﬁrst indication that
microvesicles might be involved in neurodegenerative diseases.
Indeed, microvesicles have been shown to be secreted by several
neuronal cell types, thereby contributing to the physiology and
synaptic plasticity of the central nervous system (Bellingham et al.,
2012). It is also of note, that microvesicles have been found to be
able to pass the blood–brain barrier and to deliver functional siRNA
Fig. 1. Senescent donor cells contribute to the senescence-associated secretory phenotype (SASP) by secreting not only soluble proteins but also microvesicles either in a paracrine,
endocrine or synaptic manner. These vesicles are taken up by recipient cells and may cause or contribute to age related pathologies like osteoporosis, atherosclerosis, Alzheimer's
disease or diabetes mellitus, type 2.
631S. Weilner et al. / Experimental Gerontology 48 (2013) 626–633to neurons (Alvarez-Erviti et al., 2011), which opens up the possibil-
ity of cross talk via this usually very tight and selective barrier.
Furthermore, microvesicles from Alzheimer's patients have been
found to be enriched in Aβ, its precursor protein APP and some
components of γ-secretase and might thereby contribute to the
spread of Alzheimer's disease (Vella et al., 2008). Surprisingly,
microvesicles isolated from the cerebrospinal ﬂuid of diseased pa-
tients contain around 60 differentially expressed miRNAs compared
to healthy controls (Cogswell et al., 2008). So far it is unclear, if
these miRNAs might in consequence also be involved in the patho-
genic mechanisms of Alzheimer's disease, but the ﬁndings again
support the importance of microvesicular miRNAs which might
serve at least as biomarkers of diseases like Alzheimer's disease.
9.3. Diabetes mellitus, type 2 (T2DM)
The number of patients suffering from T2DM is dramatically
increasing in developed and developing countries (Zimmet et al., 2001).
First indications of deregulated microvesicular miRNAs in plasma
of patients suffering from T2DM compared to healthy age and sex
matched controls are available and provide a potential diagnostic
signature containing 5 miRNAs, including reduced miR-126 level
(Zampetaki et al., 2010).
Interestingly, it was already demonstrated that increased miR-126
level promote vascular endothelial growth factor (VEGF) signaling
and has a positive effect on vascular protection (Zernecke et al.,
2009). It is known that the monocytes of patients suffering from
T2DM exhibit reduced VEGF sensitivity which is contributing to an
impaired collateral vessel development. This effect might be due to
a reduced microvesicular transport of miR-126 to monocytes
(Zampetaki et al., 2010).
9.4. Osteoporosis
So far, no study has addressed secreted miRNA in bone disorders
of the elderly, however, it is conceivable that miRNAs will be associat-
ed with this disease as well, since several miRNAs are known to be
regulated during osteogenic differentiation (reviewed by Schraml
and Grillari, 2012).
Recently our group could show that microvesicles originating
from senescent endothelial cells are taken up by MSCs thereby
inhibiting osteogenesis via miR-31 delivery Weilner, Schraml andGrillari, unpublished observations. Additionally, circulating miR-31
levels were also found to be signiﬁcantly increased in plasma of do-
nors older than 55 as well as in patients suffering from osteopenia
compared to donors younger than 25 years Weilner, Schraml and
Grillari, unpublished observations.
These results might provide a link between the age associated
incidence of reduced bone healing or osteopenia and accumulating
senescent endothelial cells with age in vivo.10. Concluding remarks
The still quite recent identiﬁcation of secreted and/ormicrovesicular
miRNAs in the systemic environment, in interstitial ﬂuids or other body
ﬂuids poses a formidable tool to identify and use miRNAs as diagnostic
signatures. Developing such signatures is of high concern as personal-
ized medication and therapy depends on “personalized” diagnostic
tools. The here presented examples of miRNAs that are associated or
sometimes even causally linked to age-associated diseases might pro-
vide such a toolbox of biomarkers. As small non-coding RNAs have
been used in clinical trials by now,miRNAswill certainly alsoﬁnd appli-
cations as therapeutic targets. Especially for thosemiRNAs that circulate
in the systemic environment, drug targeting might be comparably easy
due to good accessibility in the blood.Acknowledgments
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